Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

SRZN

Surrozen, Inc./DE

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1824893Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$3.0M
Net Income FY2025
$(242.0M)
EPS (Basic, as reported)
—
Net Margin FY2025
-6960.8%
ROE FY2025
128.9%
Total Equity
$(188.0M)
Shares Out
12M
Business description

Surrozen, Inc./DE — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 3
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Revenue—0130113
Research & development(26)(40)(37)(27)(21)(29)
General & administrative(7)(14)(20)(16)(15)(16)
Total operating expenses(33)(54)(57)(46)(36)(46)
Operating income(33)(54)(44)(46)(26)(42)
Interest & investment income001223
Other income (expense), net0080(19)(26)
Pre-tax income————(64)(242)
Income tax expense000000
Net income(33)(55)(36)(43)(64)(242)
EPS — basic——————
EPS — diluted——————
Shares outstanding — basic (M)—00000
Shares outstanding — diluted (M)—00000

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.